Seminars in Oncology
Volume 33 , Pages 26-32 , April 2006

The Role of Gemcitabine in First-Line Treatment of Advanced Ovarian Carcinoma

  • Tate Thigpen

      Affiliations

    • Prof Thigpen has served as a consultant and invited speaker for Eli Lilly & Co.
    • Corresponding Author InformationAddress reprint requests to Prof Tate Thigpen, University of Mississippi School of Medicine, 2500 N State St, Jackson, MS 39216.

References 

  1. Omura G , Blessing J , Ehrlich C , et al.   A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study . Cancer . 1986;57:1725–1730
  2. Omura G , Bundy B , Berek J , et al.   Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma (A Gynecologic Oncology Group study) . J Clin Oncol . 1989;7:457–465
  3. The International Collaborative Ovarian Neoplasm (ICON) Group . ICON2 (Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer) . Lancet . 1998;352:1571–1576
  4. Thigpen T , Blessing J , Ball H , et al.   Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy (A Gynecologic Oncology Group study) . J Clin Oncol . 1994;12:1748–1753
  5. Einzig A , Wiernik P , Sasloff J , et al.   Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma . J Clin Oncol . 1992;10:1748–1753
  6. McGuire W , Rowinsky E , Rosenshein N , et al.   Taxol (A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms) . Ann Intern Med . 1989;111:273–279
  7. Kohn E , Sarosy G , Bicher A , et al.   Dose-intense taxol (high response rate in patients with platinum-resistant recurrent ovarian cancer) . J Natl Cancer Inst . 1994;86:18–24
  8. Verschraegen C , Sittisomwong T , Kudelka A , et al.   Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma . J Clin Oncol . 2000;18:2733–2739
  9. Francis P , Schneider J , Hann L , et al.   Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer . J Clin Oncol . 1994;12:2301–2308
  10. Kaye S , Piccart M , Aapro M , et al.   Phase II trials of docetaxel (taxotere) in advanced ovarian cancer–An updated overview . Eur J Cancer . 1997;33:2167–2170
  11. Rose P , Blessing J , Ball H , et al.   A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma (A Gynecologic Oncology Group study) . Gynec Oncol . 2003;88:130–135
  12. Piccart M , Gore M , Ten Bokkel Huinink W , et al.   Docetaxel (An active new drug for treatment of advanced epithelial ovarian cancer) . J Natl Cancer Inst . 1995;87:676–681
  13. Kudelka A , Tresukosol D , Edwards C , et al.   Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma . J Clin Oncol . 1996;14:1552–1557
  14. Creemers G , Bolis G , Gore M , et al.   Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer (Results of a large European phase II study) . J Clin Oncol . 1996;14:3056–3061
  15. ten Bokkel Huinink W , Gore M , Carmichael J , et al.   Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer . J Clin Oncol . 1997;15:2183–2193
  16. McGuire W , Blessing J , Bookman M , et al.   Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma (A Gynecologic Oncology Group Study) . J Clin Oncol . 2000;18:1062–1067
  17. Bookman M , Malmstrom H , Bolis G , et al.   Topotecan for the treatment of advanced epithelial ovarian cancer (An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel) . J Clin Oncol . 1998;16:3345–3352
  18. Muggia F , Hainsworth J , Jeffers S , et al.   Phase II study of liposomal doxorubicin in refractory ovarian cancer (Antitumor activity and toxicity modification by liposomal encapsulation) . J Clin Oncol . 1997;15:987–993
  19. Gordon A , Granai C , Rose P , et al.   Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer . J Clin Oncol . 2000;18:3093–3100
  20. Gordon A , Fleagle J , Guthrie D , et al.   Recurrent epithelial ovarian carcinoma (A randomized phase III study of pegylated liposomal doxorubicin versus topotecan) . J Clin Oncol . 2001;19:3312–3322
  21. Markman M , Kennedy A , Webster K , et al.   Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum . Gynecol Oncol . 2000;78:369–372
  22. Rose P , Maxson J , Fusco N , et al.   Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma (A retrospective comparative study of single-agent dosages) . Gynecol Oncol . 2001;82:323–328
  23. Campos S , Penson R , Mays A , et al.   The clinical utility of liposomal doxorubicin in recurrent ovarian cancer . Gynecol Oncol . 2001;81:206–212
  24. Rose P , Blessing J , Mayer A , et al.   Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma (A Gynecologic Oncology Group study) . J Clin Oncol . 1998;16:405–410
  25. Hoskins P , Swenerton K . Oral etoposide is active against platinum-resistant epithelial ovarian cancer . J Clin Oncol . 1994;12:60–63
  26. Seymour M , Mansi J , Gallagher C , et al.   Protracted oral etoposide in epithelial ovarian cancer (A phase II study in patients with relapsed or platinum-resistant disease) . Br J Cancer . 1994;69:191–195
  27. Markman M , Hakes T , Reichman B , et al.   Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer . J Cancer Res Clin Oncol . 1992;119:55–57
  28. Tuxen M , Lund B , Hansen O , et al.   Oral etoposide in elderly previously untreated ovarian cancer patients with residual disease . Int J Gynecol Cancer . 1997;7:213–217
  29. Friedlander M , Millward M , Bell D , et al.   A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer . Ann Oncol . 1998;9:1343–1345
  30. Shapiro J , Millward M , Rischin D , et al.   Activity of gemcitabine in patients with advanced ovarian cancer (Responses seen following platinum and paclitaxel) . Gynecol Oncol . 1996;63:89–93
  31. Lund B , Hansen O , Theilade K , et al.   Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients . J Natl Cancer Inst . 1994;86:1530–1533
  32. George M , Heron J , Kerbrat P , et al.   Navelbine in advanced ovarian epithelial cancer (A study of the French Oncology Centers) . Semin Oncol . 1989;16(suppl 4):30–32
  33. Sorensen P , Hoyer M , Jakobsen A , et al.   Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma . Gynecol Oncol . 2001;81:58–62
  34. Burger R , DiSaia P , Roberts J , et al.   Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer . Gynecol Oncol . 1999;72:148–153
  35. Gershenson D , Burke T , Morris M , et al.   A phase I study of daily ×3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer . Gynecol Oncol . 1998;70:404–409
  36. Bajetta E , Di Leo A , Biganzoli L , et al.   Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer (Activity in platinum-resistant disease) . J Clin Oncol . 1996;14:2546–2551
  37. Look K , Muss H , Blessing J , et al.   A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma (A Gynecologic Oncology Group study) . Am J Clin Oncol . 1995;18:19–22
  38. McGuire WP , Hoskins WJ , Brady MF , et al.   Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer . N Engl J Med . 1996;334:1–6
  39. Piccart MJ , Bertelsen K , James K , et al.   Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer (Three-year results) . J Natl Cancer Inst . 2000;92:699–708
  40. du Bois A , Luck H , Meier W , et al.   A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer . J Natl Cancer Inst . 2003;95:1320–1329
  41. Ozols R , Bundy B , Greer B , et al.   Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer (A Gynecologic Oncology Group study) . J Clin Oncol . 2003;21:3194–3200
  42. Thigpen T , Stuart G , du Bois A , et al.   Clinical trials in ovarian carcinoma (Requirements for standard approaches and regimens) . Ann Oncol . 2005;16(suppl 8):13–19
  43. Peters G , Bergman A , Ruiz van Haperen V , et al.   Interaction between cisplatin and gemcitabine in vitro and in vivo . Semin Oncol . 1995;22(suppl 11):72–79
  44. Thigpen T . The role of gemcitabine-based doublets in the management of ovarian carcinoma . Semin Oncol . 2002;29(suppl 1):11–16
  45. Belpomme D , Krakowski I , Beauduin M , et al.   Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer (A phase II study) . Gynecol Oncol . 2003;91:32–38
  46. Nogue M , Cirera L , Arcusa A , et al.   Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer . Anticancer Drugs . 2002;13:839–845
  47. Bauknecht T , Hefti A , Morack G , et al.   Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer (A phase II study) . Int J Gynecol Cancer . 2005;15:180–181
  48. Muggia F , Braly P , Brady M , et al.   Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer (A Gynecologic Oncology Group study) . J Clin Oncol . 2000;18:106–115
  49. Bookman MA . Developmental chemotherapy in advanced ovarian cancer (Incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG 182)) . Semin Oncol . 2002;29(suppl 1):20–31
  50. Copeland LJ , Bookman M , Trimble E . Clinical trials of newer regimens for treating ovarian cancer (The rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5) . Gynecol Oncol . 2003;90:S1–S7
  51. Iaffaioli RV , Tortoriello A , Facchini G , et al.   Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non–small-cell lung cancer . J Clin Oncol . 1999;17:921–926
  52. Pedersen AG . Phase I studies of gemcitabine combined with carboplatin or paclitaxel . Semin Oncol . 1997;24(suppl 7):64–68
  53. Gupta SK , John S , Naik R , et al.   A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaive advanced ovarian cancer . Gynecol Oncol . 2005;98:134–140
  54. Hansen SW . Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma . Semin Oncol . 2002;29(suppl 1):17–19
  55. Look KY , Bookman MA , Schol J , et al.   Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer (A Gynecologic Oncology Group study) . Gynecol Oncol . 2004;92:93–100
  56. Micha JP , Goldstein BH , Rettenmaier MA , et al.   Pilot study of outpatient paclitaxel, carboplatin, and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer . Gynecol Oncol . 2004;94:719–724
  57. du Bois A , Belau A , Wagner U , et al.   A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8) . Gynecol Oncol . 2005;96:444–451
  58. Berkenblit A , Tung N , Kim Y , et al.   Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of mullerian origin . Gynecol Oncol . 2003;89:486–493
  59. Harries M , Moss C , Perren T , et al.   A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer . Br J Cancer . 2004;91:627–632

PII: S0093-7754(06)00122-9

doi: 10.1053/j.seminoncol.2006.03.015

Seminars in Oncology
Volume 33 , Pages 26-32 , April 2006

Article Tools